These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 9223752)

  • 21. Trimethoprim-sulfamethoxazole prophylaxis in sub-Saharan Africa.
    Anglaret X
    Lancet; 2001 Sep; 358(9287):1027-8. PubMed ID: 11589928
    [No Abstract]   [Full Text] [Related]  

  • 22. Recommendations for fungal opportunistic infections prevention in persons infected with human immunodeficiency virus.
    Popa LG; Popa MI; Zaharia A; Ocneanu M
    Roum Arch Microbiol Immunol; 1999; 58(2):185-95. PubMed ID: 11845456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Empirical treatment for PCP in HIV-infected patients--justified?
    Hamide A; Dutta TK; Vasireddy S
    J Assoc Physicians India; 1995 Jan; 43(1):70-1. PubMed ID: 9282655
    [No Abstract]   [Full Text] [Related]  

  • 24. Cotrimoxazole prophylaxis for HIV-positive TB patients in developing countries.
    Zachariah R; Massaquoi M
    Trop Doct; 2006 Apr; 36(2):79-82. PubMed ID: 16611438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study finds NAC fails to prevent Bactrim/Septra hypersensitivity.
    TreatmentUpdate; 1999 Feb; 11(1):4-5. PubMed ID: 11366023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Considering the benefits of disease-specific interventions on overall public health.
    Boyd M; Byakwaga H
    Lancet Infect Dis; 2008 May; 8(5):278. PubMed ID: 18471772
    [No Abstract]   [Full Text] [Related]  

  • 27. Compliance with cotrimoxazole prophylaxis for the prevention of opportunistic infections in HIV-positive tuberculosis patients in Thyolo district, Malawi.
    Zachariah R; Harries AD; Arendt V; Wennig R; Schneider S; Spielmann M; Panarotto E; Gomani P; Salaniponi FM
    Int J Tuberc Lung Dis; 2001 Sep; 5(9):843-6. PubMed ID: 11573896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cotrimoxazole prophylaxis in HIV-infected individuals after completing anti-tuberculosis treatment in Thyolo, Malawi.
    Zachariah R; Spielmann MP; Harries AD; Gomani P; Bakali E
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1046-50. PubMed ID: 12546111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults?
    Hamel MJ; Greene C; Chiller T; Ouma P; Polyak C; Otieno K; Williamson J; Shi YP; Feikin DR; Marston B; Brooks JT; Poe A; Zhou Z; Ochieng B; Mintz E; Slutsker L
    Am J Trop Med Hyg; 2008 Sep; 79(3):320-30. PubMed ID: 18784222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pneumocystis carinii pneumonia (PCP) in HIV-infected African children.
    Zar HJ
    SADJ; 2001 Dec; 56(12):617-9. PubMed ID: 11887451
    [No Abstract]   [Full Text] [Related]  

  • 31. Reconsidering empirical cotrimoxazole prophylaxis for infants exposed to HIV infection.
    Gill CJ; Sabin LL; Tham J; Hamer DH
    Bull World Health Organ; 2004 Apr; 82(4):290-7. PubMed ID: 15259258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Acute encephalopathy caused by sulfadiazine and trimethoprim-sulfamethoxazole in a patient with AIDS].
    Arjol AM; Sánchez C; Dalmau D
    Enferm Infecc Microbiol Clin; 1998 May; 16(5):250-1. PubMed ID: 9666594
    [No Abstract]   [Full Text] [Related]  

  • 33. [Exanthema in multiple therapy in HIV infection].
    Weisser M
    Praxis (Bern 1994); 1998 May; 87(20):702-4. PubMed ID: 9633229
    [No Abstract]   [Full Text] [Related]  

  • 34. Co-trimoxazole prophylaxis in tropical countries in the era of highly active antiretroviral therapy: do we know enough?
    Lynen L; Jacobs J; Colebunders R
    Trans R Soc Trop Med Hyg; 2007 Nov; 101(11):1059-60. PubMed ID: 17662321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Balancing individual benefit against public health risk: the impact of cotrimoxazole prophylaxis in HIV-infected patients on antimicrobial resistance.
    Hamer DH; Gill CJ
    Am J Trop Med Hyg; 2008 Sep; 79(3):299-300. PubMed ID: 18784218
    [No Abstract]   [Full Text] [Related]  

  • 36. Zidovudine therapy protects against Salmonella bacteremia recurrence in human immunodeficiency virus-infected patients.
    Casado JL; Valdezate S; Calderon C; Navas E; Frutos B; Guerrero A; Martinez-Beltran J
    J Infect Dis; 1999 Jun; 179(6):1553-6. PubMed ID: 10228081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New perspectives in the chemotherapy of toxoplasmosis.
    Terragna A; Canessa A
    J Chemother; 1989 Jul; 1(4 Suppl):935-7. PubMed ID: 16312712
    [No Abstract]   [Full Text] [Related]  

  • 38. [Update on consensual proposals (1993 February). Role of cotrimoxazole in the primary prevention of toxoplasmosis in patients with HIV infection].
    Leport C; Ambroise-Thomas P; Chêne G; Derouin F; Katlama C; Raffi F; Vildé JL
    Ann Med Interne (Paris); 1993; 144(1):56-7. PubMed ID: 8503612
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of trimethoprim-sulfamethoxazole prophylaxis on etiology and susceptibilities of pathogens causing human immunodeficiency virus-associated bacteremia.
    Wininger DA; Fass RJ
    Antimicrob Agents Chemother; 2002 Feb; 46(2):594-7. PubMed ID: 11796387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Managing a patient with progressive HIV disease.
    Blais FX
    J Am Osteopath Assoc; 1992 Oct; 92(10):1267-8. PubMed ID: 1459873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.